human kappa light chain Search Results


hrp  (Novus Biologicals)
93
Novus Biologicals hrp
Hrp, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hrp/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
hrp - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti human immunoglobulin kappa chain  (R&D Systems)
94
R&D Systems anti human immunoglobulin kappa chain
Anti Human Immunoglobulin Kappa Chain, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human immunoglobulin kappa chain/product/R&D Systems
Average 94 stars, based on 1 article reviews
anti human immunoglobulin kappa chain - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
human kappa light chain  (Novus Biologicals)
91
Novus Biologicals human kappa light chain
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Human Kappa Light Chain, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human kappa light chain/product/Novus Biologicals
Average 91 stars, based on 1 article reviews
human kappa light chain - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
polyclonal goat anti human kappa light chain antibodies conjugated to hrp  (Novus Biologicals)
90
Novus Biologicals polyclonal goat anti human kappa light chain antibodies conjugated to hrp
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Polyclonal Goat Anti Human Kappa Light Chain Antibodies Conjugated To Hrp, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal goat anti human kappa light chain antibodies conjugated to hrp/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
polyclonal goat anti human kappa light chain antibodies conjugated to hrp - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
rabbit anti human pan cytokeratin  (Novus Biologicals)
93
Novus Biologicals rabbit anti human pan cytokeratin
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Rabbit Anti Human Pan Cytokeratin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti human pan cytokeratin/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
rabbit anti human pan cytokeratin - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
goat anti human kappa antibody  (Novus Biologicals)
90
Novus Biologicals goat anti human kappa antibody
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Goat Anti Human Kappa Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti human kappa antibody/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
goat anti human kappa antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
biotinylated rabbit anti human igm  (Valiant Co Ltd)
95
Valiant Co Ltd biotinylated rabbit anti human igm
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Biotinylated Rabbit Anti Human Igm, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated rabbit anti human igm/product/Valiant Co Ltd
Average 95 stars, based on 1 article reviews
biotinylated rabbit anti human igm - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
goat anti human kappa light chain secondary antibody  (Bio-Rad)
93
Bio-Rad goat anti human kappa light chain secondary antibody
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Goat Anti Human Kappa Light Chain Secondary Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti human kappa light chain secondary antibody/product/Bio-Rad
Average 93 stars, based on 1 article reviews
goat anti human kappa light chain secondary antibody - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
human kappa light chain antibody  (Bethyl)
93
Bethyl human kappa light chain antibody
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Human Kappa Light Chain Antibody, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human kappa light chain antibody/product/Bethyl
Average 93 stars, based on 1 article reviews
human kappa light chain antibody - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
human ig kappa light chain  (R&D Systems)
93
R&D Systems human ig kappa light chain
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Human Ig Kappa Light Chain, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ig kappa light chain/product/R&D Systems
Average 93 stars, based on 1 article reviews
human ig kappa light chain - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
goat anti human kappa biotin  (Vector Laboratories)
92
Vector Laboratories goat anti human kappa biotin
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Goat Anti Human Kappa Biotin, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti human kappa biotin/product/Vector Laboratories
Average 92 stars, based on 1 article reviews
goat anti human kappa biotin - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

Image Search Results


Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor H, IgD, ITIH1, ITIH2, and kappa light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting Plasmodium falciparum cytoadherence.

doi: 10.1073/pnas.2104166118

Figure Lengend Snippet: Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor H, IgD, ITIH1, ITIH2, and kappa light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.

Article Snippet: For binding inhibition assays, serum and serum fractions (at 10%), recombinant human attractin (7238-AT-050; Novus Biologicals), C1s (A104; Complement Technology; or 2060-SE; R&D Systems), human complement C4b (H00000721-Q01; Novus Biologicals), human complement factor H (H00003075-P03; Novus Biologicals), IgD (NB100-62667; Novus Biologicals), human kappa light chain (H00003514-P01; Novus Biologicals), human inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) (H00003697-P01; Novus Biologicals), and H2 (ITIH2) (NBP2-31750PEP; Novus Biologicals) (at physiological concentrations in serum, ∼10% of the physiological concentrations or an estimated concentration where serum levels could not be found; see SI Appendix, Table S1) were added to the parasites in DMEM binding medium immediately before coincubation with HBEC-5i.

Techniques: Binding Assay, Fractionation, Size-exclusion Chromatography, Control, Tandem Mass Spectroscopy